Data from randomized clinical trials have supported the safety and efficacy of intravenous
tissue-type plasminogen activator (IV tPA) for acute ischemic stroke when administered …

Background: Intravenous tissue plasminogen activator (IV tPA) is currently approved by the
Food and Drug Administration for use in acute ischemic stroke patients up to 3 h from …

Importance Pooled analysis of randomized controlled trials of intravenous thrombolysis
shows no statistically significant benefit beyond 4.5 hours, with the possible advantage …

Background Intravenous tissue plasminogen activator (tPA) is the only approved therapy for
acute ischemic stroke, although only 2% of patients with stroke receive intravenous tPA …

Association Stroke Council include specific recommendations for the administration of
intravenous recombinant tissue plasminogen activator (rtPA). 1 Despite its effectiveness in …

Background and Purpose—The feasibility, safety, and efficacy of intravenous tissue
plasminogen activator (t-PA) for patients with acute ischemic stroke in clinical practice need …

Ischemic stroke is a major cause of morbidity and mortality for which the only approved
treatment in the acute setting is intravenous thrombolysis. The efficacy and safety of …

Background: Extending the therapeutic window for thrombolysis is an important strategy in
maximizing the proportion of patients treated. ECASS III examined a 3–4.5-hour window and …

The results of the pivotal intravenous tissue plasminogen activator (tPA) trials have been
reported and its use approved for acute ischemic stroke treatment for nearly 10 years [1–3] …

Background and Purpose—Only a single study has demonstrated beneficial effects of
intravenous tissue plasminogen activator (tPA) in stroke patients. Methods—We evaluated …